Ceftizoxime: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) m (Changed protection level for "Ceftizoxime" ([Edit=Allow only autoconfirmed users] (expires 03:36, 14 January 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 03:36, 14 January 2014 (UTC)))) |
Gerald Chi (talk | contribs) m (→US Brand Names) |
||
| Line 11: | Line 11: | ||
==US Brand Names== | ==US Brand Names== | ||
CEFIZOX<sup>®</sup> | |||
CEFIZOX | |||
==FDA Package Insert== | ==FDA Package Insert== | ||
Revision as of 03:39, 31 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Ceftizoxime is a third-generation cephalosporin available for parenteral administration.
Unlike other 3rd generation cephalosporins, in ceftizoxime the whole C-3 side chain has been removed to prevent deactivation by hydrolytic enzymes. It rather resembles cefotaxime in its properties, but is not subjected to metabolism.
Category
US Brand Names
CEFIZOX®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Labels and Packages